Add Granules India Ltd for Target Rs.835 by Choice Institutional Equities
We visited Granules’ Gagillapur and Genome Valley facilities and had a detailed interaction with Mr. Krishna Prasad Chigurupati, Chairman, Ms. Priyanka Chigurupati, Executive Director, Mr. Mukesh Surana, CFO and Mr. Sanjay Kumar, CSO. The visit provided valuable insights into the company’s ongoing efforts to strengthen quality systems, accelerate digital transformation and enhance manufacturing efficiency through automation. The management highlighted that remediation activities at Gagillapur are largely complete, while Genome Valley continues to gain strategic importance as a key manufacturing and business continuity hub. We believe the acquisition of Senn Chemicals positions GRAN favorably to capitalise on the growing peptides opportunity and will be a key driver of long-term growth, while the company’s expanding oncology pipeline further strengthens its future prospects. Over the medium term, growth is expected to be supported by continued momentum in the FD segment, scale-up of the Genome Valley facility, and normalisation of operations at Gagillapur following the completion of remediation measures. We continue to expect to see a CAGR of 18.4%/19.5%/25.4% over FY26–29E and maintain our ‘ADD’ rating with an unchanged TP of INR 835
Key Observations:
* The management indicated that more than 90% of remediation actions at Gagillapur have been completed and the facility has formally communicated its readiness for USFDA re-inspection.
* The company continues to strengthen data integrity and quality systems through MES and LIMS implementation and is working towards paper less organisation.
* Genome Valley (GLS) provides meaningful contingency support, with 28 products transferred from Gagillapur and approvals progressing.
* Automation initiatives such as continuous coating and automated cleaning systems are improving productivity while reducing operator dependency.
* Over the medium term, the management expects growth to be driven by integrated products, complex generics, controlled substances and peptide-related opportunities.
Key Discussion Themes:
* Regulatory Recovery on Track: The management acknowledged that the September 2024 observations represented a significant event for the organisation, particularly given the facility's strong compliance track record. Since then, the focus has shifted from observation closure towards building sustainable systems and quality processes.
* Manufacturing Becoming More Digital: A recurring theme across discussions was the increasing use of digital systems to improve compliance, traceability and operational efficiency. The management believes paperless manufacturing and laboratory operations will significantly strengthen quality oversight going forward.
* GLS Provides Strategic Flexibility: The GLS facility not only serves as a contingency site but also provides capacity headroom for future growth and supports the company's broader complex products strategy.
Gagillapur Facility
* The Gagillapur facility remains the company's largest finished dosage manufacturing site and plays a critical role within Granules' integrated manufacturing network.
* The site encompasses granulation, compression, coating, inspection, packing and warehousing operations.
* A notable addition is the MUPS block, which integrates multiple manufacturing stages while reducing material handling requirements and improving process efficiency.
For Detailed Report With Disclaimer Visit. https://choicebroking.in/disclaimer
SEBI Registration no.: INZ 000160131
